Spectranetics selloff on Q2 results warranted, says Northland Northland views the post-earnings pullback in shares of Spectranetics as warranted and remains negative on the company's fundamentals. The lowered FY15 revenue "set off alarm bells" and the company's explanations for growth rates "provided a confusing picture," the firm tells investors in a research note.
Spectranetics guidance is balance of downside/upside scenarios, says Canaccord Canaccord believes Spectranetics' disappointing guidance will lead to a lower valuation for shares, but the firm sees it as a better balance of downside/upside scenarios. The firm said the company's best chance for redemption is better execution and does not believe its core business in VI and LM has vanished. Canaccord maintained its Buy rating but lowered its price target to $26.50 from $36 on Spectranetics shares.